TLDR:
- Leiden-based Vico Therapeutics secures €11.5M in funding from Seroba and Kurma Partners in a Series B financing round.
- The funding will help advance the development of therapies for severe neurological diseases.
Leiden-based Vico Therapeutics, a genetic medicines company, has raised €11.5M in a second closing of a Series B financing round from Seroba and Kurma Partners. The funding comes after a successful initial round of €54M earlier this year. The total Series B financing round now stands at €65.8M, with contributions from existing investors, such as Ackermans & van Haaren, Droia Ventures, and EQT Life Sciences. Vico Therapeutics, founded in 2019, is focused on developing therapies for severe neurological diseases. Its lead program, VO659, is currently in a Phase 1/2a clinical study for patients with spinocerebellar ataxia types 3 and 1 and Huntington’s disease.
The company’s platform, VICOMER, utilizes precision chemistry to design ASOs that modulate RNA through various approaches. This funding will help Vico Therapeutics advance its therapies for patients with genetic neurological disorders. Seroba, a Dublin-based venture capital firm, and Kurma Partners, a European VC firm, have shown support for the company. With this funding, Vico Therapeutics aims to make significant progress in treating severe neurological diseases and delivering life-changing outcomes for patients.
Overall, Vico Therapeutics’ latest funding round will bolster its clinical programs and support the advancement of RNA-modulating therapies for severe genetic neurological disorders, paving the way for innovative treatments in the field of health tech and medtech.
